Rehmann Capital Advisory Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Rehmann Capital Advisory Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$779K	Sell	4,925 -82	-2%	-$11.1K	0.04%	322
2026 Q1	$640K	Buy	5,007 +10	+0.2%	+$1.25K	0.03%	347
2025 Q4	$609K	Buy	4,997 +2	+0%	+$229	0.03%	348
2025 Q3	$501K	Sell	4,995 -151	-3%	-$13.6K	0.03%	380
2025 Q2	$427K	Sell	5,146 -145	-3%	-$11.6K	0.03%	386
2025 Q1	$429K	Hold	5,291	–	–	0.03%	393
2024 Q4	$477K	Buy	5,291 +345	+7%	+$33.4K	0.03%	361
2024 Q3	$489K	Hold	4,946	–	–	0.03%	342
2024 Q2	$459K	Buy	4,946 +2,356	+91%	+$211K	0.03%	342
2024 Q1	$246K	Buy	+2,590	New	+$240K	0.02%	505
2021 Q4	–	Sell	-2,205	Closed	-$277K	–	591
2021 Q3	$277K	Hold	2,205	–	–	0.03%	454
2021 Q2	$299K	Buy	2,205 +280	+15%	+$36.8K	0.03%	432
2021 Q1	$261K	Buy	+1,925	New	+$288K	0.03%	441
2019 Q3	–	Sell	-929	Closed	-$81.5K	–	2157
2019 Q2	$81.5K	Sell	929 -14	-1%	-$1.19K	0.01%	677
2019 Q1	$85.3K	Sell	943 -74,454	-99%	-$6.33M	0.01%	642
2018 Q4	$2.8M	Buy	75,397 +73,962	+5,154%	+$5.96M	0.42%	30
2018 Q3	$138K	Buy	1,435 +356	+33%	+$34.5K	0.02%	500
2018 Q2	$103K	Buy	1,079 +300	+39%	+$27.6K	0.01%	558
2018 Q1	$68K	Buy	+779	New	+$71.1K	0.01%	661

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Rehmann Capital Advisory Group's XBI Position: Q2 2026 in Review

Rehmann Capital Advisory Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.6% in Q2 2026, selling an estimated $11.1K and leaving 4,925 shares worth $779K. The position accounts for 0.04% of the portfolio, ranked #322.

Rehmann Capital Advisory Group first reported a position in XBI in Q1 2018 and has held it in 19 quarters since. The position peaked at $2.8M in Q4 2018. 934 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Rehmann Capital Advisory Group held 4,925 shares of State Street SPDR S&P Biotech ETF worth $779K as of Q2 2026.
Rehmann Capital Advisory Group sold 82 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $11.1K.
State Street SPDR S&P Biotech ETF made up 0.04% of Rehmann Capital Advisory Group's portfolio in Q2 2026, its #322 holding.
Rehmann Capital Advisory Group first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and has held it in 19 quarters since.
Rehmann Capital Advisory Group's State Street SPDR S&P Biotech ETF position peaked at $2.8M in Q4 2018.
934 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q2 2026, filed 20 Aug 2026.